Currently out of the existing stock ratings of Drew Ranieri, 94 are a BUY (42.73%), 93 are a HOLD (42.27%), 33 are a SELL (15%).

Drew Ranieri

Work Performance Price Targets & Ratings Chart

Analyst Drew Ranieri, currently employed at MORGAN STANLEY, carries an average stock price target met ratio of 62.81% that have a potential upside of 16.96% achieved within 121 days.

Drew Ranieri’s has documented 455 price targets and ratings displayed on 23 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on ORGO, Organogenesis Holdings at 05-Mar-2025.

Wall Street Analyst Drew Ranieri

Analyst best performing recommendations are on NPCE (NEUROPACE).
The best stock recommendation documented was for NPCE (NEUROPACE) at 8/24/2023. The price target of $6 was fulfilled within 1 day with a profit of $0.84 (16.28%) receiving and performance score of 162.79.

Average potential price target upside

of $35.78 (13.53%) on SYK (STRYKER).
of $20.64 (6.42%) on ISRG (INTUITIVE SURGICAL).
of $14.69 (12.9%) on ZBH (ZIMMER BIOMET HOLDINGS).

AGTI Agiliti BVS Bioventus GMED Globus Medical HAE Haemonetics HRC Hill-Rom Holdings ISRG Intuitive Surgical NPCE Neuropace NUVA NuVasive SIBN Si-Bone SYK Stryker TMCI Treace Medical Concepts ZBH Zimmer Biomet Holdings ATEC Alphatec Holdings AVNS Avanos Medical BAX Baxter International IART Integra LifeSciences Holdings NVST Envista Holdings Corp OM Outset Medical TFX Teleflex STVN Stevanato Group SpA ORGO Organogenesis Holdings BDX Becton Dickinson and Company EMBC Embecta Corp

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

John Ransom (RAYMOND JAMES)

Hold Since 26-Mar-2024

2 years 6 months 27 days ago
(26-Mar-2024)

1/6 (16.67%)

$4.31 (27.47%)

Please subscribe to see extended stock data

Kevin Caliendo (UBS)

Buy Since 07-Mar-2024

$10

$-0.05 (-0.50%)

$10

2 years 7 months 16 days ago
(07-Mar-2024)

4/5 (80%)

$0.1 (1.01%)

Please subscribe to see extended stock data

Brian Tanquilut (JEFFERIES)

Buy Since 25-Sep-2023

$10.5

2 years 7 months 26 days ago
(27-Feb-2024)

0/1 (0%)

$3.69 (54.19%)

Please subscribe to see extended stock data

Drew Ranieri (MORGAN STANLEY)

Sell Since 14-Nov-2023

2 years 7 months 27 days ago
(26-Feb-2024)

5/10 (50%)

$0.17 (2.17%)

Please subscribe to see extended stock data

Kevin Fischbeck (BAML)

Hold Since 09-Aug-2023

$11

$0.95 (9.45%)

$18

3 years 1 months 18 days ago
(05-Sep-2023)

1/3 (33.33%)

$2.29 (26.29%)

Please subscribe to see extended stock data

Show more analysts

Please expand the browser size to see the chart

What Year was the first public recommendation made by Drew Ranieri?

On 2021